UroGen Pharma’s (URGN) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a research report report published on Thursday morning,Benzinga reports. They currently have a $25.00 target price on the stock.

Several other equities analysts have also recently commented on URGN. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of UroGen Pharma in a research note on Tuesday, October 15th. Oppenheimer reiterated an “outperform” rating and issued a $40.00 target price on shares of UroGen Pharma in a research note on Wednesday, October 16th. Finally, EF Hutton Acquisition Co. I raised UroGen Pharma to a “strong-buy” rating in a research report on Monday, October 14th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $43.70.

UroGen Pharma Trading Up 0.9 %

UroGen Pharma stock opened at $10.24 on Thursday. UroGen Pharma has a 52 week low of $9.78 and a 52 week high of $20.70. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The firm has a market capitalization of $240.17 million, a PE ratio of -3.25 and a beta of 1.09. The business’s 50-day simple moving average is $11.20 and its 200-day simple moving average is $12.95.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.29. The business had revenue of $25.20 million during the quarter, compared to the consensus estimate of $24.22 million. During the same period in the prior year, the firm earned ($0.68) earnings per share. Equities research analysts forecast that UroGen Pharma will post -3.1 earnings per share for the current year.

Institutional Trading of UroGen Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. raised its holdings in shares of UroGen Pharma by 90.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock worth $103,000 after buying an additional 3,856 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in UroGen Pharma by 221.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after purchasing an additional 5,890 shares in the last quarter. ProShare Advisors LLC acquired a new stake in shares of UroGen Pharma in the second quarter valued at $199,000. Intech Investment Management LLC acquired a new position in UroGen Pharma during the 3rd quarter worth about $155,000. Finally, Verition Fund Management LLC acquired a new position in shares of UroGen Pharma during the third quarter worth approximately $168,000. Institutional investors own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.